How does this affect clinicians today?

How does this affect clinicians today?

Cleveland Clinic

2 months
7 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Kailin Yang, MD of Cleveland Clinic answers how this will affect clinicians today and questions asked by his colleagues.

_______

Inhibiting two critical steps in the metabolism of glioblastoma stem cells (GSCs) attenuates GSC self-renewal and reduces tumorigenesis, finds a new study presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).

“Determining how to target glioma stem cells effectively has been a major challenge in treating glioblastoma [GBM],” says Kailin Yang, MD, PhD, a radiation oncology resident at Cleveland Clinic Cancer Center who presented the abstract under the supervision of Jeremy Rich, MD, MHS, of the University of California at San Diego. “Our previous studies suggested that pyrimidine synthesis is associated with clinical outcome in glioblastoma patients, and thus is a productive place to focus our energy.”

The current study demonstrates that simultaneous targeting of two vital enzymes in the pyrimidine synthetic pathway inhibits self-renewal and tumorigenesis of GSCs.

The first enzyme is rate-limiting carbamoyl-phosphate synthetase 2, aspartate transcarbamyolase, dihydroorotase (CAD). EGFR or PTEN driver mutations demonstrated distinct CAD phosphorylation patterns. The second, dihydroorotate dehydrogenase (DHODH), catalyzes the subsequent step in pyrimidine synthesis after CAD. Targeting both enzymes with clinically approved inhibitors produced sustained inhibition of the survival, self-renewal and in vivo tumor initiation of GSCs in patient-derived xenografts, when compared with single treatments.

Read the rest here: https://consultqd.clevelandclinic.org/metabolic-reprogramming-a-promising-approach-to-tackling-therapeutic-resistance-in-glioblastoma/ 

Up Next Autoplay
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
0 Views
ash 1 hour
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
Category: Multiple Myeloma
1 Views
ash 1 hour
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
Category: Multiple Myeloma
2 Views
ash 2 hours
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
Category: Immunotherapy
0 Views
Cancer-News 3 hours
How Sensitive is the Technology? @PennMedicine @sellmyerlab
How Sensitive is the Technology? @PennMedicine @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 3 hours
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 3 hours
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
4 Views
iCMLf 1 day
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
2 Views
iCMLf 1 day
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research  through study of von Hippel-Lindau (VHL) disease
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 1 day
Re-evaluating TKI in CML Patients During Pregnancy
Re-evaluating TKI in CML Patients During Pregnancy
Category: Chronic Myelogenous Leukemia
2 Views
iCMLf 1 day